MYDA Advisors LLC acquired a new position in Aimmune Therapeutics Inc (NASDAQ:AIMT) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $378,000.
Several other hedge funds have also modified their holdings of AIMT. First Republic Investment Management Inc. purchased a new stake in shares of Aimmune Therapeutics in the fourth quarter worth $202,000. SG Americas Securities LLC raised its position in Aimmune Therapeutics by 54.7% during the third quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 2,979 shares in the last quarter. Virtu Financial LLC purchased a new stake in Aimmune Therapeutics during the fourth quarter valued at about $239,000. Daiwa SB Investments Ltd. raised its position in Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 2,245 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Aimmune Therapeutics during the fourth quarter valued at about $282,000. Institutional investors own 62.04% of the company’s stock.
In other news, insider Susan E. Barrowcliffe sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $37.14, for a total transaction of $2,785,500.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Eric Bjerkholt acquired 3,125 shares of Aimmune Therapeutics stock in a transaction dated Monday, February 26th. The shares were bought at an average cost of $32.00 per share, for a total transaction of $100,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 58,093 shares of company stock worth $1,858,976 and have sold 133,968 shares worth $5,073,180. 17.59% of the stock is currently owned by company insiders.
Shares of Aimmune Therapeutics Inc (AIMT) traded up $0.28 during trading hours on Wednesday, hitting $33.28. The stock had a trading volume of 709,999 shares, compared to its average volume of 1,420,000. Aimmune Therapeutics Inc has a 52-week low of $15.97 and a 52-week high of $42.00. The company has a market capitalization of $1,690.00 and a PE ratio of -16.08.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/03/14/myda-advisors-llc-acquires-new-position-in-aimmune-therapeutics-inc-aimt.html.
Aimmune Therapeutics Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.